Tripp, Catherine S <br/><br/>
RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.  [electronic resource] 

 -  Advances in therapy  06 2017 
 - 1364-1381 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1865-8652 
<br/><br/><label>Standard No.: </label>10.1007/s12325-017-0525-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Asthma--drug therapy<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Interleukin-13--antagonists & inhibitors<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Middle Aged<br/>Young Adult